Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions.

Introduction Percutaneous coronary intervention (PCI) in long coronary lesions still remains a challenge for the interventional cardiologist. Although the incidence of restenosis after drug-eluting stent (DES) implantation is relatively low, current literature indicates that stent overlapping is associated with major adverse cardiac events (MACE)1. The novel BioMimeTM (Meril Life Sciences, Vapi, Gujarat, India) 60 mm-long sirolimus-eluting coronary stent system with tapered design has recently been commercialised and is emerging as an interesting tool for patients with long and diffuse coronary lesions2,3. Therefore, the aim of the present work was to describe our initial experience with this new DES.